Federal
Published: Oct 18, 2019
Tagged in: Access to Affordable Medicines, Value-based Pricing Assessments
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
Federal
Published: Oct 18, 2019
Tagged in: Access to Affordable Medicines, Value-based Pricing Assessments
NORD comments to the Institute for Clinical and Economic Review’s (ICER) value assessment framework for 2020
Published: Jun 10, 2019
Tagged in: Access to Affordable Medicines, Value-based Pricing Assessments
NORD comments to the Institute for Clinical and Economic Review (ICER) on a proposed adaptation to its value framework for the assessment of treatments for ultra-rare conditions
Published: Sep 25, 2017
Tagged in: Access to Affordable Medicines, Value-based Pricing Assessments
NORD comments on proposed changes to ICER’s value framework
Published: Apr 3, 2017
Tagged in: Access to Affordable Medicines, Value-based Pricing Assessments
NORD comments on ICER’s Patient Participation Guide
Published: Apr 3, 2017
Tagged in: Access to Affordable Medicines, Value-based Pricing Assessments